Yan Jianlong, Pan Yanbin, He Yaqiong, Wang Rongning, Shao Wenming, Dong Shaohong
Jinan University, Guangzhou, Guangdong, China.
Department of Cardiology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, 518020, Guangdong, China.
Heart Vessels. 2020 Oct;35(10):1419-1428. doi: 10.1007/s00380-020-01613-0. Epub 2020 May 3.
The effects of serum iron level without anemia on long-term prognosis of patients with coronary heart disease (CHD) complicated with chronic heart failure (CHF) is still unclear. The objective of this study was to explore the effects of serum iron level without anemia on long-term prognosis of patients with CHD complicated with CHF. In this retrospective cohort study, 221 patients with CHD complicated with CHF were consecutively investigated. These patients were divided into three groups according to the tertiles of the serum iron level: low-iron group (n = 71), medium-iron group (n = 76) and high-iron group (n = 74). The overall serum iron without anemia was 13.0 ± 5.50 μmol/L and serum iron in each group was 7.58 ± 1.63 μmol/L, 11.94 ± 1.79 μmol/L, and 19.37 ± 3.81 μmol/L, respectively. Composite endpoint events were composed of major adverse cardiovascular and cerebrovascular events (MACCE), including recurrent heart failure, all-cause death, acute coronary syndrome (ACS) and ischemic stroke. The median follow-up duration was 239 days. After adjusting relevant confounding risk factors, we found that excessively low or high serum iron level is correlated to the MACCE in patients with CHD complicated with CHF and that the prognosis of patients with excessively high serum iron level is poorer than that of patients with excessively low serum iron level. We further revealed the effect of serum iron level on MACCE is U-shaped, but not linear relationship. Sensitivity analysis showed that the correlation between serum iron level and MACCE is stable. In addition, according to the test for interaction, the variables that modify the effect including CRP (P for interaction < 0.0001), diuretics (P for interaction = 0.0212) and antiplatelet drugs (P for interaction = 0.0167). This study showed that excessively low or high serum iron level without anemia is an independent risk factor of MACCE in patients with CHD complicating with CHF.
无贫血状态下血清铁水平对冠心病(CHD)合并慢性心力衰竭(CHF)患者长期预后的影响尚不清楚。本研究的目的是探讨无贫血状态下血清铁水平对CHD合并CHF患者长期预后的影响。在这项回顾性队列研究中,连续纳入了221例CHD合并CHF患者。这些患者根据血清铁水平的三分位数分为三组:低铁组(n = 71)、中铁组(n = 76)和高铁组(n = 74)。无贫血状态下的总体血清铁水平为13.0±5.50μmol/L,每组的血清铁水平分别为7.58±1.63μmol/L、11.94±1.79μmol/L和19.37±3.81μmol/L。复合终点事件包括主要不良心血管和脑血管事件(MACCE),包括复发性心力衰竭、全因死亡、急性冠状动脉综合征(ACS)和缺血性卒中。中位随访时间为239天。在调整相关混杂风险因素后,我们发现血清铁水平过低或过高均与CHD合并CHF患者的MACCE相关,且血清铁水平过高患者的预后比血清铁水平过低患者更差。我们进一步揭示血清铁水平对MACCE的影响呈U形,而非线性关系。敏感性分析表明血清铁水平与MACCE之间的相关性是稳定的。此外,根据交互作用检验,影响该效应的变量包括C反应蛋白(CRP,交互作用P<0.0001)、利尿剂(交互作用P = 0.0212)和抗血小板药物(交互作用P = 0.0167)。本研究表明,无贫血状态下血清铁水平过低或过高是CHD合并CHF患者发生MACCE的独立危险因素。